↓ Skip to main content

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
4 X users
patent
4 patents

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density
Published in
Journal of Bone & Mineral Research, February 2015
DOI 10.1002/jbmr.2489
Pubmed ID
Authors
Abstract

Administration of blosozumab, a humanized monoclonal antibody that binds sclerostin, increases bone formation and BMD in postmenopausal women with low BMD. To evaluate the effect of discontinuing blosozumab, we studied women enrolled in a 1-year randomized, placebo-controlled Phase 2 trial for an additional year after they completed treatment. Of the 120 women initially enrolled in the study, 106 women completed treatment and continued into follow-up; 88 women completed 1-year of follow-up. At the beginning of follow-up, groups remained balanced for age, race, and body mass index, but lumbar spine and total hip BMD were increased for prior blosozumab groups, reflecting an anabolic treatment effect. At the end of follow-up, one year after discontinuing treatment, lumbar spine BMD remained significantly greater than placebo in women initially treated with blosozumab 270 mg every 2 weeks (Q2W), and blosozumab 180 mg Q2W (6.9% and 3.6% above baseline, respectively). Total hip BMD also declined following discontinuation of treatment, but at one year after treatment remained significantly greater than placebo in women initially treated with blosozumab 270 mg Q2W and blosozumab 180 mg Q2W (3.9% and 2.6% above baseline, respectively). During follow-up, median serum P1NP was not consistently different between the prior blosozumab groups and placebo. A similar pattern was apparent for median serum CTx levels, with more variability. Mean serum total sclerostin concentration increased with blosozumab, indicating target engagement, and declined to baseline following discontinuation. There were no adverse events considered related to prior treatment with blosozumab. Anti-drug antibodies generally declined in patients who had detectable levels during prior treatment. These findings support the continued study of blosozumab as an anabolic therapy for treatment of osteoporosis. This article is protected by copyright. All rights reserved.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 13 17%
Student > Ph. D. Student 9 12%
Student > Master 7 9%
Professor 6 8%
Other 5 7%
Other 9 12%
Unknown 26 35%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 16 21%
Agricultural and Biological Sciences 7 9%
Biochemistry, Genetics and Molecular Biology 6 8%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Sports and Recreations 2 3%
Other 8 11%
Unknown 32 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#6,107,983
of 34,454,098 outputs
Outputs from Journal of Bone & Mineral Research
#1,609
of 5,759 outputs
Outputs of similar age
#57,446
of 296,047 outputs
Outputs of similar age from Journal of Bone & Mineral Research
#14
of 53 outputs
Altmetric has tracked 34,454,098 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,759 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,047 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.